cancer

NIH Book Talk Highlights IRP Cancer Research

"A Fatal Inheritance" Author Larry Ingrassia Discusses His New Book

Lawrence Ingrassia at the NIH event

In June 2024, Mr. Lawrence Ingrassia visited NIH to give a talk about his book, A Fatal Inheritance: How a Family Misfortune Revealed a Medical Mystery, which evolved from interviews with current and former IRP researchers, including IRP scientist emeritus Joseph F. Fraumeni, Jr., M.D.

Li-Fraumeni Syndrome (LFS) is an inherited disorder caused by deleterious variants in the TP53 tumor-suppressor gene that lead to very elevated risk of cancers, including sarcomas, brain, breast, and many others. Investigators at NIH have followed families with LFS since the syndrome was first described in 1969 by Dr. Fraumeni and his late collaborator, Dr. Frederick P. Li. Drs. Li and Fraumeni’s seminal discovery was the foundation on which studies of genetic susceptibility to cancer were built.

Software Tool Guides Breast Cancer Care

IRP’s Jinani Jayasekera Hopes to Help Women Make Medical Decisions

doctor using a tablet to access medical software

The women in our lives deserve flowers and thanks on Mother’s Day, but they also deserve attention to their well-being. This past Sunday, May 12, marked the start of Women’s Health Week, a time to reflect on the decisions women make to look after their own health.

For instance, breast cancer treatments are something no woman wants to think about, but every year about 240,000 newly diagnosed women in the U.S. face high-stakes decisions about what medical interventions to pursue. IRP Stadtman investigator Jinani Jayasekera, Ph.D., and her colleagues in the IRP’s Health Equity and Decision Sciences (HEADS) lab develop software-based clinical decision-making tools to help women and their doctors assess and address their health risks when choosing treatments.

Symposium Spotlights Promising Female Scientists

Annual Event Recognizes Three Young Researchers’ Scientific Accomplishments

Dr. Jennifer Zink

For decades, NIH has been working to solve the problems that have long stymied the careers of many young women interested in becoming scientists. As that essential effort continues, it’s important to shine a spotlight on some of the talented female researchers who are contributing to our knowledge of human health and biology right now.

One way the IRP does that is through the annual NIH Women Scientists Advisors (WSA) Scholar Award Symposium, which each year gives three early-career female scientists working in NIH labs the opportunity to present their work to the entire IRP community. At this year’s symposium, which took place April 29, the most recent group to be named WSA Scholars by NIH’s Women Scientists Advisors committee discussed their efforts to probe pollution’s impact on health, improve immunotherapy for cancer, and examine how screen time affects kids. Read on to learn more about their award-winning research.

Breaking Down the Meat We Eat

IRP Research Explores the Health Effects of Specific Dietary Components

examining a raw steak with a magnifying glass

When Hippocrates said, “Let food by thy medicine and medicine thy food,” he was on to something. That’s why National Nutrition Month, celebrated every March, calls attention to the important link between health and diet. To commemorate Nutrition Month this year, we spoke with IRP senior investigator Rashmi Sinha, Ph.D., about her efforts to tease out not only which foods help or harm out bodies, but why they do so.

Determining the health effects of different foods has long been a holy grail in research, but with so many variables, our knowledge remains vague at best. Some foods — processed meats, certain fats, sugar — clearly have negative effects when eaten in large amounts, while others like green vegetables and legumes are helpful. Unfortunately, there are a lot of unknowns in between.

NIH Mourns the Passing of Dilys Parry

Dr. Dilys Parry

Dr. Dilys Parry died peacefully in her sleep in the early morning of February 2, 2024, after a long illness. For 30 years, Dr. Parry was a staff clinician and principal investigator in the Division of Cancer Epidemiology and Genetics (DCEG) at NIH's National Cancer Institute (NCI). Following her retirement from federal service in 2007 she continued to engage with her colleagues on projects as a special volunteer. 

Dr. Parry’s medical genetics research focused primarily on genetic and clinical studies of neurofibromatosis 2 (NF2) and chordoma, a rare bone tumor derived from the notochord, and adult brain tumors. She was deeply committed to educating patients about the natural history of these diseases and helping them and at-risk relatives receive genetic testing or other types of screening to aid in early detection and treatment. Her research helped to identify susceptibility genes for and delineate the spectrum of clinical manifestations associated with NF2 and chordoma. She also elucidated correlations between the specific types of variants in the gene NF2 and clinical findings. Much of the momentum that exists in chordoma research traces back to Dr. Parry’s early interest in the disease.

Alternative Therapy Relieves Immunotherapy’s Neurological Consequences

Case Studies Highlight New Way to Treat Common Side Effect

child with cancer

New medical treatments nearly always come packaged with new side effects. CAR-T cell therapy, a game-changing ‘immunotherapy’ for cancer, is no exception. However, a set of case studies reported by IRP researchers could help physicians better contend with one of the therapy’s most worrisome complications.

CAR-T cell therapy involves collecting immune cells called T cells from a patient's blood, genetically modifying them to turn them into cancer killers, growing millions of the modified cells in the lab, and then returning the cancer-seeking missiles to the patient’s body. As promising as the approach is for eliminating cancer, the first CAR-T cell therapy was approved by the U.S. Food and Drug Administration (FDA) only a bit more than six years ago, so clinicians are still figuring out the best ways to manage its less desirable effects.

HHS Awards Recognize IRP Cancer Researchers

Long Careers at NIH Yield Groundbreaking Achievements

from left to right: Dr. Robert Yarchoan, Dr. Elaine Jaffe, and Dr. Louis Staudt

When you work at the National Institutes of Health, major advances in health and science can seem like a regular occurrence. Yet not all advances are created equal; some change entire paradigms for understanding and treating disease, even disarming a disease’s lethal effects.

This fall, three IRP senior investigators received Departmental Awards from the United States Department of Health and Human Services (HHS) for their exceptional contributions to science: Louis M. Staudt, M.D., Ph.D., Elaine S. Jaffe, M.D., and Robert Yarchoan, M.D. Dr. Staudt received the HHS Secretary’s Award for Distinguished Service for his revolutionary work on the diagnosis and treatment of diffuse large B-cell lymphoma (DLBCL); Dr. Jaffe received the Secretary’s Award for Meritorious Service for her pioneering discoveries about lymphomas and blood cancers; and Dr. Yarchoan received the HHS Career Achievement Award for his role in developing the first effective drugs for AIDS and developing treatments for HIV-associated cancers.

Postdoc Profile: Where the Climate Meets Community Health

Dr. Richard Remigio Studies the Health Repercussions of Changing Environmental Conditions

Dr. Richard Remigio

Summer 2023 started off on an ominous note. On June 7th, New Yorkers woke up to a deep orange skyline over Manhattan and the Statue of Liberty, resembling a scene from a dystopian novel. Air quality indices there reached ‘code maroon,’ warning that being outdoors was dangerous even for healthy people. Americans and Europeans would subsequently endure some of the highest summer temperatures on record, and in August, wildfires devastated the Hawaiian island of Maui.

These and many other recent events have made it clear how much climate change already affects people’s lives. One of the people trying to combat those consequences is Richard Remigio, Ph.D., a postdoctoral fellow at the Occupational and Environmental Epidemiology Branch at the National Cancer Institute (NCI).

New Lasker Scholars Are Coming for Cancer

IRP Program Supports Cutting-Edge Cancer Research

Dr. Rosa Nguyen

The cumulative years of experience among the IRP’s large cadre of cancer researchers is truly astounding, with numerous scientists having spent half a century or more studying the disease at NIH. As incredibly valuable as their hard-earned wisdom is to finding new treatments for cancer, any scientific field also benefits tremendously from a constant influx of young talent. That’s where the IRP’s Lasker Clinical Research Scholars Program comes in.

The Lasker program identifies extremely promising early-career physician-scientists in a wide variety of fields and provides them with funding and resources to start their own independent labs at NIH. Over the past year, purely by coincidence, all of the Lasker Scholars selected happen to specialize in the study and treatment of cancer. Read on to learn more about the new ideas and bounding enthusiasm these fresh faces are bringing to NIH’s fight against the disease.

Fighting the Fungus Among Us

Overactive Immune Response Sets Stage for Infection

various fungi growing in a petri dish

Fungal infections are a serious medical threat to many people, especially those who are critically ill or have weakened immune systems. What’s more, outbreaks are on the rise, as studies show that rising global temperatures are causing fungi to evolve into new strains and grow in regions that were once too cold for comfort. Recent outbreaks include a tragic incident at a Michigan paper mill that sickened nearly 100 people and caused one death, as well as a cluster of fungal infections that have killed at least seven women who underwent cosmetic surgery at clinics in Mexico.

Commemorating Fungal Disease Awareness Week this week brings attention to the importance of combating fungal threats to our well-being. The theme this year is ‘Think Fungus,’ and that’s exactly what IRP senior investigator Michail Lionakis, M.D., Sc.D., has been doing for the last 20 years.